Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. [electronic resource]
Producer: 20170626Description: 777-84 p. digitalISSN:- 1941-837X
- Abiraterone Acetate -- economics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- economics
- Benzamides
- Clinical Trials, Phase III as Topic
- Costs and Cost Analysis
- Disease Progression
- Disease-Free Survival
- Drug Therapy, Combination
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Nitriles
- Phenylthiohydantoin -- analogs & derivatives
- Prednisone -- economics
- Prostate-Specific Antigen
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.